Relmada Therapeutics (RLMD) Cash from Investing Activities (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Cash from Investing Activities for 13 consecutive years, with -$135.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 980.4% year-over-year to -$135.2 million; the TTM figure through Mar 2026 stood at -$198.7 million (down 449.48% YoY), while the FY2025 annual figure was -$48.1 million, down 193.36% from the prior year.
• Cash from Investing Activities slipped to -$135.2 million in Q1 2026 per RLMD's latest filing, from -$76.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $40.0 million in Q1 2023 and bottomed at -$135.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$3.6 million across 5 years, with a median of $6.8 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 1316.79% — and 2026, when it slumped 980.4%.
• Relmada Therapeutics' Cash from Investing Activities stood at -$1.7 million in 2022, then surged by 567.62% to $7.7 million in 2023, then jumped by 46.56% to $11.3 million in 2024, then slumped by 778.07% to -$76.9 million in 2025, then sank by 75.78% to -$135.2 million in 2026.
• Business Quant data shows RLMD's Cash from Investing Activities at -$135.2 million in Q1 2026, -$76.9 million in Q4 2025, and $6.8 million in Q3 2025.